A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour

Title

Code

TANGENT

Type

Sperimentale con farmaco

Start Year

2024

Status

In Corso

Principal Investigator

051-6366101

emanuela.palmerini@ior.it

Palmerini Emanuela, MD

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies

Operational unit that carry out the study

complex unit

Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative

Director

Ibrahim Toni, BSc, MSc, MD, PhD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. TANGENT

Tuesday 3 September 2024, 14:26

PG0012906_2024_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in